On Nov 14, major Wall Street analysts update their ratings for $Progyny (PGNY.US)$, with price targets ranging from $17 to $22.
BofA Securities analyst Allen Lutz maintains with a buy rating, and maintains the target price at $21.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $30 to $17.
Jefferies analyst Glen Santangelo maintains with a buy rating, and adjusts the target price from $24 to $19.
Cantor Fitzgerald analyst Sarah James maintains with a buy rating, and adjusts the target price from $25 to $22.
Furthermore, according to the comprehensive report, the opinions of $Progyny (PGNY.US)$'s main analysts recently are as follows:
Progyny's stock experienced an 11% decline following the earnings announcement. This was a result of better-than-anticipated selling season outcomes being eclipsed by repeated reductions concerning atypical usage, which has raised concerns regarding forecasting models. While there is an anticipation for evidence of accurate forecasting, there is also an acknowledgment of the need for a more cautious outlook on the company's guidance.
Q3 results indicate continuing pressure due to an unfavorable utilization mix, and there's limited visibility on when these conditions might shift. Despite the uncertainty caused by utilization trends, there remains a positive outlook on the fertility end-market and Progyny's dominant market position.
The firm is revising its projections to account for the outcomes of the selling season. This includes the addition of 1.1 million members, which is somewhat offset by approximately 700,000 due to a previously disclosed client departure. Additionally, the firm is adopting a more cautious stance on the expected utilization and composition for Q4 and the full year of FY25.
Here are the latest investment ratings and price targets for $Progyny (PGNY.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月14日，多家華爾街大行更新了$Progyny (PGNY.US)$的評級，目標價介於17美元至22美元。
美銀證券分析師Allen Lutz維持買入評級，維持目標價21美元。
巴克萊銀行分析師Stephanie Davis維持買入評級，並將目標價從30美元下調至17美元。
富瑞集團分析師Glen Santangelo維持買入評級，並將目標價從24美元下調至19美元。
坎托·菲茨杰拉德分析師Sarah James維持買入評級，並將目標價從25美元下調至22美元。
此外，綜合報道，$Progyny (PGNY.US)$近期主要分析師觀點如下：
Progyny的股票在盈利公告後經歷了11%的下跌。這是由於好於預期的銷售季節結果被關於不尋常使用的反覆下調所遮蓋，這引發了對預測模型的擔憂。儘管人們期待有準確預測的證據，但也承認對公司指引的前景需要更加謹慎。
第三季度的結果表明，由於不利的利用組合，壓力仍在持續，並且對這些條件何時可能變化的可見性有限。儘管由於利用趨勢引發的不確定性，生育終端市場和Progyny的市場主導地位仍然保持積極的前景。
該公司正在修訂其預測，以考慮銷售季節的結果。這包括新增110萬會員，但由於先前披露的客戶離開，約有70萬會員的影響部分抵消。此外，公司對第四季度及2025財年的預期利用率和組成採取了更加謹慎的態度。
以下爲今日4位分析師對$Progyny (PGNY.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
